Study of the Efficacy of Maintenance Therapy Using Uracil-tegafur (UFT) or Bacille Calmette-Guerin (BCG) for the Prevention of Recurrences of Superficial Bladder Cancer (EMBARK Study)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this prospective randomized controlled study is to prove the non-inferiority of UFT maintenance therapy to BCG maintenance therapy for preventing recurrences of superficial bladder cancer.
| Condition | Intervention | Phase |
|---|---|---|
|
Bladder Cancer |
Drug: Bacille Calmette-Guerin Drug: uracil-tegafur |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study |
- Relapse-free survival rate [ Time Frame: Three-year ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 288 |
| Study Start Date: | January 2010 |
| Estimated Study Completion Date: | December 2019 |
| Estimated Primary Completion Date: | December 2017 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: BCG maintenance therapy |
Drug: Bacille Calmette-Guerin
The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
|
| Experimental: UFT maintenance therapy |
Drug: uracil-tegafur
The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
|
Detailed Description:
Patients who have undergone transurethral resection of a superficial bladder tumor (TUR-Bt) and BCG induction therapy are eligible for enrollment in this study. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt.
The patients will be randomly assigned to a BCG maintenance therapy arm or a UFT maintenance therapy arm. The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for BCG maintenance therapy will be the same as that used for BCG induction therapy. Patients in the UFT maintenance therapy arm will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
The primary endpoint of this study is the three-year relapse-free survival rate.
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Superficial bladder cancer
- Completion of transurethral resection of bladder tumor (TUR-Bt)
- Completion of BCG induction therapy after TUR-Bt. In principle, BCG induction therapy consists of the successive weekly intravesical administration of 81 mg of BCG-Connaught strain or 80 mg of BCG-Japan strain for 6 weeks after the completion of TUR-Bt.
- Age 20 to 80 years
- ECOG performance status of 0 or 1
- Bladder capacity ≥ 150 mL
- Capable of oral UFT administration
- Expected life prognosis ≥ 3 years
- Hematopoietic WBC ≥ 3,000/mm^3
- Neutrophil ≥ 1,500/mm^3
- Platelet ≥ 100,000/mm^3
- Hepatic AST and ALT ≤ 2 times upper limit of normal (ULN)
- Total bilirubin ≤ 1.5 mg/dL
- Hemoglobin ≤ 9.0 g/dL
- Creatinine ≤ 1.5 mg/dL
Exclusion Criteria:
- Bladder cancer located in prostatic part of the urethra
- Anamnesis of bladder cancer classified as cT2, cT3 or cT4
- Anamnesis of metastatic bladder cancer
- Anamnesis of upper urinary tract carcinoma in situ
- Anamnestic treatment of intravesical BCG administration within previous 6 months
- Prior anticancer chemotherapy or radiotherapy
- Severe complication
- Presence of contraindications for the administration of BCG or UFT
- Pregnancy, lactation
Contacts and Locations| Contact: Satoru Muto, PhD | +81 3 3964 2497 | muto@med.teikyo-u.ac.jp |
| Japan | |
| Department of Urology, Teikyo University Hospital | Recruiting |
| Itabashi-ku, Tokyo, Japan | |
| Contact: Shigeo Horie, PhD +81 3 3964 2497 shorie@med.teikyo-u.ac.jp | |
More Information
No publications provided
| Responsible Party: | Shigeo Horie, Department of Urology, Teikyo University Hospital |
| ClinicalTrials.gov Identifier: | NCT01082510 History of Changes |
| Other Study ID Numbers: | EMBARK |
| Study First Received: | March 5, 2010 |
| Last Updated: | March 22, 2011 |
| Health Authority: | Japan: Institutional Review Board |
Keywords provided by Urological Oncology Council of Northern Tokyo:
|
UFT BCG |
Additional relevant MeSH terms:
|
Urinary Bladder Neoplasms Recurrence Urologic Neoplasms Urogenital Neoplasms Neoplasms by Site Neoplasms Urinary Bladder Diseases Urologic Diseases Disease Attributes |
Pathologic Processes Tegafur Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Antineoplastic Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on June 17, 2013